# US 2024/0189328 A1 · Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189328 A1
- Document ID: US20240189328A1
- Status: Published application
- Kind: A1
- Application number: 18/286,399
- Filed: 2022-04-15
- Published: 2024-06-13
- Earliest claimed: 2021-04-16
- Assignees: Apnimed, Inc. (Delaware)
- Applicants: Apnimed, Inc. (Delaware)
- Inventors: Lawrence G. MILLER; Luigi TARANTO-MONTEMURRO; Ronald FARKAS; David P. WHITE
- Web page: https://patentgrep.com/patent/US20240189328A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/433: Thidiazoles
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/04: for throat disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI) and a cannabinoid and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI) and methods of treating sleep apnea are described herein.

## Claims

### Claim 1

A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 3 (depends on 2)

The method of claim 2, wherein the NSRI is selected from the group consisting of amedalin, atomoxetine, CP-39,332, daledalin, edivoxetine, esreboxetine, lortalamine, nisoxetine, reboxetine, talopram, talsupram, tandamine, and viloxazine, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of amitriptiline, amoxapine, bupropion, ciclazindol, desipramine, desvenlafaxine, dexmethilphenidate, diethylpropion, doxepin, duloxetine, imipramine, levomilnacipran, manifaxine, maprotiline, methylphenidate, milnacipran, nefazodone, nortriptyline, phendimetrazine, phenmetrazine, protryptyline, radafaxine, tapentadol, teniloxazine, and venlafaxine, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the NRI is reboxetine or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the NRI is atomoxetine or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the cannabinoid is selected from the group consisting of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA), or any combination thereof, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cannabinoid is CBD.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cannabinoid is THC.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cannabinoid is dronabinol.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, further comprising administering to the subject (iii) a muscarinic receptor antagonist (MRA).

### Claim 12 (depends on 11)

The method of claim 11, wherein the MRA is selected from the group consisting of atropine, propantheline, bethanechol, solifenacin, darifenacin, tolterodine, fesoterodine, trospium, and oxybutynin, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 11)

The method of any claim 11, wherein the MRA is selected from the group consisting of anisotropine, benztropine, biperiden, clidinium, cycrimine, dicyclomine, diphemanil, diphenidol, ethopropazine, glycopyrrolate, hexocyclium, isopropamide, mepenzolate, methixene, methscopolamine, oxyphencyclimine, oxyphenonium, procyclidine, scopolamine, tridihexethyl, and trihexyphenidyl, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the MRA is oxybutynin or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the MRA is (R)-oxybutynin or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the atomoxetine or pharmaceutically acceptable salt thereof is administered at a dose of from about 20 to about 200 mg.

### Claim 17 (depends on 16)

The method of claim 16 wherein the atomoxetine or pharmaceutically acceptable salt thereof is administered at a dose of from about 25 to about 100 mg.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein CBD is administered at a dose of from about 0.5 to about 300 mg.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17 wherein THC is administered at a dose of from about 0.1 to about 30 mg.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 11-19, wherein the oxybutynin or pharmaceutically acceptable salt thereof is administered at a dose of from about 1 to about 15 mg.

### Claim 21 (depends on 20)

The method of claim 20, wherein the oxybutynin or pharmaceutically acceptable salt thereof is administered at a dose of from about 2 mg to about 10 mg.

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 11-19, wherein the (R)-oxybutynin or pharmaceutically acceptable salt thereof is administered at a dose of from about 0.5 to about 10 mg.

### Claim 23 (depends on 22)

The method of claim 22, wherein the (R)-oxybutynin or pharmaceutically acceptable salt thereof is administered at a dose of from about 1 mg to about 5 mg.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, further comprising administering to the subject a carbonic anhydrase inhibitor (CAI).

### Claim 25 (depends on 24)

The method of claim 24, wherien the CAI is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherien the CAI is acetazolamide or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the NRI and cannabinoid are administered in a single composition.

### Claim 28 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 11-26, wherein the NRI, MRA, and cannabinoid are administered in a single composition.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein the single composition is an oral administration form.

### Claim 30 (depends on 29)

The method of claim 29, wherein the oral administration form is a syrup, pill, tablet, troche, capsule, or patch.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the condition associated with pharyngeal airway collapse is sleep apnea.

### Claim 32 (depends on 31)

The method of claim 31, wherein the condition associated with pharyngeal airway collapse is obstructive sleep apnea (OSA).

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the condition associated with pharyngeal airway collapse is snoring.

### Claim 34 (depends on 33)

The method of claim 33 wherein the condition associated with pharyngeal airway collapse is simple snoring.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the subject is in a non-fully conscious state, such as sleep.

### Claim 36

A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, in a pharmaceutically acceptable carrier.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 38 (depends on 37)

The composition of claim 37, wherein the NSRI is selected from the group consisting of amedalin, atomoxetine, CP-39,332, daledalin, edivoxetine, esreboxetine, lortalamine, nisoxetine, reboxetine, talopram, talsupram, tandamine, and viloxazine, or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 36)

The composition of claim 36, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of amitriptiline, amoxapine, bupropion, ciclazindol, desipramine, desvenlafaxine, dexmethilphenidate, diethylpropion, doxepin, duloxetine, imipramine, levomilnacipran, manifaxine, maprotiline, methylphenidate, milnacipran, nefazodone, nortriptyline, phendimetrazine, phenmetrazine, protryptyline, radafaxine, tapentadol, teniloxazine, and venlafaxine, or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 36)

The composition of claim 36, wherein the NRI is reboxetine or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 36)

The composition of claim 36, wherein the NRI is atomoxetine or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The composition of any one of claims 36-41, wherein the cannabinoid is selected from the group consisting of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA), or any combination thereof, or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the cannabinoid is CBD.

### Claim 44 (depends on 42)

The composition of claim 42, wherein the cannabinoid is THC.

### Claim 45 (depends on 36)

The composition of claim 36, wherein the cannabinoid is dronabinol.

### Claim 46 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The composition of any one of claims 36-45, further comprising (iii) a muscarinic receptor antagonist (MRA).

### Claim 47 (depends on 46)

The composition of claim 46, wherein the MRA is selected from the group consisting of atropine, propantheline, bethanechol, solifenacin, darifenacin, tolterodine, fesoterodine, trospium, and oxybutynin, or a pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 46)

The composition of any claim 46, wherein the MRA is selected from the group consisting of anisotropine, benztropine, biperiden, clidinium, cycrimine, dicyclomine, diphemanil, diphenidol, ethopropazine, glycopyrrolate, hexocyclium, isopropamide, mepenzolate, methixene, methscopolamine, oxyphencyclimine, oxyphenonium, procyclidine, scopolamine, tridihexethyl, and trihexyphenidyl, or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 46)

The composition of claim 46, wherein the MRA is oxybutynin or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the MRA is (R)-oxybutynin or a pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The composition of any one of claims 36-50, wherein the atomoxetine or pharmaceutically acceptable salt thereof is present in an amount of from about 20 to about 200 mg.

### Claim 52 (depends on 51)

The composition of claim 51, wherein the atomoxetine or pharmaceutically acceptable salt thereof is present in an amount of from about 25 to about 100 mg.

### Claim 53 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 36-52, wherein CBD is present in an amount of from about 0.5 to about 300 mg.

### Claim 54 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 36-52 wherein THC is present in an amount of from about 0.1 to about 30 mg.

### Claim 55 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 46-54, wherein the oxybutynin or pharmaceutically acceptable salt thereof is present in an amount of from about 1 to about 15 mg.

### Claim 56 (depends on 55)

The composition of claim 55, wherein the oxybutynin or pharmaceutically acceptable salt thereof is present in an amount of from about 2 mg to about 10 mg.

### Claim 57 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 46-54, wherein the (R)-oxybutynin or pharmaceutically acceptable salt thereof is present in an amount of from about 0.5 to about 10 mg.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the (R)-oxybutynin or pharmaceutically acceptable salt thereof is present in an amount of from about 1 mg to about 5 mg.

### Claim 59 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The composition of any one of claims 36-58, further comprising a carbonic anhydrase inhibitor (CAI).

### Claim 60 (depends on 59)

The composition of claim 59, wherien the CAI is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 60)

The composition of claim 60, wherien the CAI is acetazolamide or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The composition of any one of claims 36-61, wherein the NRI and cannabinoid are formulated in a single composition.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any one of claims 46-62, wherein the NRI, MRA, and cannabinoid are formulated in a single composition.

### Claim 64 (depends on 62, 63)

The composition of claim 62 or 63, wherein the single composition is an oral administration form.

### Claim 65 (depends on 64)

The composition of claim 64, wherein the oral administration form is a syrup, pill, tablet, troche, capsule, or patch.

### Claim 66 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The composition of any one of claims 36-65, for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 67 (depends on 66)

The composition for use of claim 66, wherein the condition associated with pharyngeal airway collapse is sleep apnea.

### Claim 68 (depends on 67)

The composition for use of claim 67, wherein the condition associated with pharyngeal airway collapse is obstructive sleep apnea (OSA).

### Claim 69 (depends on 66)

The composition for use of claim 66, wherein the condition associated with pharyngeal airway collapse is snoring.

### Claim 70 (depends on 69)

The composition for use of claim 69, wherein the condition associated with pharyngeal airway collapse is simple snoring.

### Claim 71 (depends on 66, 67, 68, 69, 70)

The composition for use of any one of claims 66-70, wherein the subject is in a non-fully conscious state, such as sleep.

### Claim 72

A kit comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, and optionally (iii) a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI).

### Claim 73 (depends on 72)

The kit of claim 72, for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 74

A norepinephrine reuptake inhibitor (NRI) and a cannabinoid, and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI), for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 75

A therapeutic combination of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, and optionally (iii) a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI), for use in treating a subject having a condition associated with pharyngeal airway collapse.
